An Emerging Global Leader in the New Generation of Anti-Infective Therapies.
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
Recce’s anti-infectives have been designed with a unique mechanism of action, with the goal of re-empowering physicians with an effective treatment that may be used repeatedly against a broad range of bacteria.
- RECCE® 327 is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including antibiotic-resistant superbugs.
- RECCE® 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use.
- RECCE® 529 is a synthetic polymer anti-infective focused on viral indications following Recce’s background antiviral research.
The US Food and Drug Administration (FDA) awarded RECCE® 327 a Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Incentives Now (GAIN) Act – labelling RECCE® 327 for Fast Track designation, plus 5 years of market exclusivity post approval. Additionally, the World Health Organization (WHO) added RECCE® compounds to its list of antibacterial products in clinical development for priority pathogens.
Origin of
Recce Pharmaceuticals
Recce (pronounced Rek-ee) originates from ‘reconnaissance’, the military tactic of – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.
- Enter the human body
- Find the infection and threat (deadly bacteria and viruses)
- Eliminate the threat
- Exit without being noticed (i.e. without side effects)
Dr Graham Melrose
Recce Pharmaceuticals was founded by Dr Graham Melrose, a former Executive Director and Head of Research at Johnson & Johnson Asia Pacific and Australia. Building upon his early, independent research, Recce Pharmaceuticals was formed.
Our
Vision and Values
“To address the global health threat of antimicrobial resistance with a revolutionary portfolio of synthetic anti-infectives.”
Discover
Patent
Commercialise
As an Australian Securities Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is well placed to pursue its drug development activities with a particular focus on Indonesia, ASEAN, Australia and the United States of America.